Orchard Therapeutics PLC
Katie Snell has progressed through various roles in the healthcare industry, starting as a Children's Nurse at Barts Health NHS Trust in 2006. Katie then worked at Great Ormond Street Hospital for Children NHS Foundation Trust from 2007 to 2020, where they specialized in gene therapy research and clinical trials. In 2017, they joined UCL Great Ormond Street Institute of Child Health as the Lead Gene Therapy Research Nurse. Most recently, they have been working at Orchard Therapeutics, where they held the position of Senior Manager Medical Affairs before becoming the Associate Director of Global Medical Affairs in 2023. Throughout their career, Katie has demonstrated expertise in gene therapy research and clinical care, along with leadership and organizational skills.
Katie Snell attended Sacred Heart of Mary Girls' School in Upminster from 1995 to 2001. Katie then pursued a degree in Children's Nursing at City, University of London from 2003 to 2006. Following this, they completed a BSc in Children's High Dependency Nursing at London South Bank University from 2008 to 2013. Most recently, they acquired an MSc in Clinical Trials from UCL, graduating in 2023.
This person is not in any offices
Orchard Therapeutics PLC
3 followers
Orchard Therapeutics plc, formerly Orchard Rx Ltd, is a commercial-stage, fully-integrated biopharmaceutical company. It is engaged in manufacturing and commercialization of gene and cell therapies, position to provide transformative therapies to patients suffering from a range of rare diseases. The Company is focused on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders and hemoglobinopathies. Its portfolio includes Strimvelis, its commercial-stage gammaretroviral-based product for the treatment of ADA-SCID five lentiviral product candidates in clinical-stage development and several other product candidates in preclinical development. It is developing OTL-101 as an autologous ex vivo lentiviral gene therapy to sustainably treat patients with adenosine deaminase severe combined immunodeficiency (ADA-SCID) through a single administration.